Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
11.02
-0.75 (-6.37%)
At close: Nov 5, 2026, 4:00 PM EST
11.43
+0.41 (3.72%)
After-hours: Nov 5, 2026, 7:30 PM EST
Vir Biotechnology Revenue
Vir Biotechnology had revenue of $-188.00K in the quarter ending September 30, 2026. This brings the company's total for the last twelve months to $302.80M, up 1,695.96% year-over-year. In the year 2025, Vir Biotechnology had annual revenue of $68.56M, down -7.61%. That makes Vir Biotechnology the 14,484th largest company in the world by revenue and 2,603rd in the United States.
Revenue (ttm)
$302.80M
Revenue Growth
+1,695.96%
P/S Ratio
6.16
Revenue / Employee
$825,065
Employees
367
Market Cap
1.86B
Revenue by Geography
- Foreign 66.52M 97.0%
- United States 2.04M 3.0%
Fiscal year ended Dec 31, 2025 See the full Vir Biotechnology breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 68.56M | -5.65M | -7.61% |
| Dec 31, 2024 | 74.21M | -11.98M | -13.90% |
| Dec 31, 2023 | 86.18M | -1.53B | -94.67% |
| Dec 31, 2022 | 1.62B | 520.38M | 47.51% |
| Dec 31, 2021 | 1.10B | 1.02B | 1,334.39% |
| Dec 31, 2020 | 76.37M | 68.28M | 843.86% |
| Dec 31, 2019 | 8.09M | -2.58M | -24.16% |
| Dec 31, 2018 | 10.67M | 7.96M | 293.94% |
| Dec 31, 2017 | 2.71M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.67B |
| Sarepta Therapeutics | 1.97B |
| Harmony Biosciences Holdings | 989.36M |
| Maravai LifeSciences Holdings | 213.00M |
| Mesoblast | 120.25M |
| Agios Pharmaceuticals | 98.34M |
| Zenas BioPharma | 1.00M |
VIR News
- 16 hours ago - Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD's The Liver Meeting® 2026 and Host Investor Conference Call - Business Wire
- 1 day ago - Vir Biotechnology reports Q3 EPS (57c), consensus (75c) - TheFly
- 1 day ago - Vir Biotechnology Earnings Call Transcript: Q3 2026 - Transcripts
- 1 day ago - Vir Biotechnology Earnings release: Q3 2026 - Filings
- 1 day ago - Vir Biotechnology Slides: Q3 2026 - Filings
- 1 day ago - Vir Biotechnology Quarterly report: Q3 2026 - Filings
- 1 day ago - Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results - Business Wire
- 3 days ago - Vir Biotechnology to Participate in the Jefferies 2026 London Healthcare Conference - Business Wire